Next Generation, Genetically Targeted Cancer Treatments
The Future of Customized, Patient-Based Cancer Care
For two decades, we at Integrative Cancer Centers of America have been helping thousands of complex end-stage and nonresponsive-to-care cancer patients find advanced treatment options by utilizing a unique personalized integrative approach that goes beyond the standardized cancer treatment models. We feel very blessed and excited to have developed an amazing team, powerful technology, and one-of-a-kind treatment options all designed to help our patients outperform other facilities that have failed to yield lasting results. Patients typically learn of ICCA after other treatments, both conventional and alternative, have failed. The question is, "How does ICCA accomplish what many other facilities have failed to achieve?" And the answer is simple, personalized technology.
Our goal is to bring leading-edge technology, advanced next-level genomic diagnostics, and precision-targeted cancer treatments created from our own custom pharmacy together to help our patients achieve a greater chance at success. The difference is in the level of precision ICCA utilizes with its treatment selection. ICCA's precision, patient-based cancer treatment protocols are helping patients who have exhausted the conventional medical system and were unsuccessful when attempting natural medicine treatment options and resources. Providing access to these robust treatment options is what makes our work very special and unique. We believe human life is a gift worth fighting for; we have a responsibility to provide truly personalized and targeted care options from an unparalleled team to help save and extend human life.
A More Personalized Approach to Cancer Treatment
Like no other time in history, we have more options and targeted technologies available to our cancer patients than ever before. These advancements make all the difference for the patients who have exhausted all previous options for treatment with no success.
ICCA is a center of excellence for personalized oncology and is truly in a category all its own. Our ability to create customized treatment plans for our patients using the latest cancer targets derived from cancer antigens, genetic biomarkers, and epigenetics combined with personalized delivery of therapies gives our patients a decisive edge in the treatment of cancer. In addition, our proprietary immunotherapy options are the result of 15 years of research and development to create precision therapies that are helping improve our patients' response to care. These are options that are still, to this day, not being properly utilized in the traditional oncology world. This is the work we have been doing for two decades, and we are showing no signs of slowing down.
What we have seen clinically, is that the key to getting a positive response to treatment is to start your care as soon as possible. Many cancer patients choose to wait until their disease has progressed to an almost unmanageable state before looking to advanced treatment options. While we are still able to help these patients, treatment becomes very complex and time consuming because we are dealing with very late-stage disease as well as having to rebuild the patient's immune system from previous failed cancer treatment attempts. Patients who do come to ICCA often report having wished they had found us sooner because our approach is vastly more evolved than what they had previously been a part of.
Beyond Traditional Chemotherapy
As a front runner for advanced delivery of genetically driven cancer treatments, we at Integrative Cancer Centers of America have made it our mission to provide patients with the latest in research and technology for comprehensive cancer care. Our mantra is to go above and beyond traditional chemotherapy with personalized, precision-driven treatment options designed to potentially help improve patient outcomes. Genetically Targeted Fractionated Chemotherapy, or GTFC, is the culmination of years of research to provide a true alternative for cancer patients who have exhausted the conventional medical system's options.
GTFC utilizes advanced cancer genomic testing for treatment targeting patient-specific genetic markers and cancer chemo sensitivity that are analyzed to tailor treatment options to the patient while minimizing the dosage needed to achieve tumor kill. GTFC is designed to deliver multiple genetically targeted, metronomic-dosed chemotherapies in combination with cancer adjunctive agents to attack cancer at its weakest points while potentially reducing the negative side-effects caused by chemotherapy reducing the negative side-effects caused by chemotherapy. GTFC is administered in conjunction with customized immunotherapy and immunotherapy adjunctive agents that may help reduce the harmful effects chemotherapy can have on healthy cells, while simultaneously reinvigorating the immune system.
Advanced Options for Late-Stage and Complex Cancers
Some cancers are extremely complex and located in areas within the body that are very hard to reach or deemed inoperable, severely limiting the effectiveness of standard treatments and thus requiring specialized advanced delivery options. One such option is chemoembolization, a procedure by which physicians can deliver chemotherapy agents directly to the tumor site in various complex and difficult-to-reach locations. Integrative Cancer Centers of America is excited to have taken this technology and modified it to develop a unique form of chemoembolization called Chemo Immunotherapy Percutaneous Injection, or CIPI™.
CIPI™ is an advanced form of chemoembolization specifically designed for tumors that are difficult to penetrate through conventional intravenous and oral chemotherapy administration methods. The personalized, micro-dosed, combination of genetically targeted medications are injected directly into the tumor through interventional radiology methods and are then sealed inside the tumor allowing for precision drug delivery and potentially improved tumor kill. By examining the patient's miRNA, circulating tumor cell DNA, and tumor mutations, CIPI™ utilizes genetic information to design a personalized treatment protocol with the chemo-genetic and immuno-genetic targets discovered from not only your tumor, but also from your unique genetic make-up.
In our clinical opinion; genetically driven, personalized precision treatment is the only way to properly fight late-stage and complex cancers. ICCA has invested years of research into developing the ability to create a complete medical blueprint for patients that can take the guess work out of treatment and provide a protocol that can be better designed to attack your unique cancer and condition.
If you or a loved one are suffering from late-stage or complex cancers, there is a lot more to find out about the kinds of uniquely personalized cancer treatment regimens we have available. Integrative Cancer Centers of America's cancer treatments may be the personalized integrative medicine that you've been searching for, customized specifically for you. Give us a call today at 866-456-6532 and speak with one of our Patient Care Coordinators. Our medical staff is well trained and able to answer any questions you might have. May God bless you on your journey to healing.